Strategies to enhance CAR-T persistence
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse h...
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
BMC
2022-11-01
|
| Edice: | Biomarker Research |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s40364-022-00434-9 |